Enveda is a multi-asset clinical-stage biotech discovering and developing novel small-molecule medicines by learning from life’s vast untapped chemical diversity with the world’s most performant AI models for metabolomics. In just a little over five years and at 1/4th the time and 1/10th the cost of industry standards, Enveda has built a pipeline of 14 distinct assets and advanced three of them into U.S. clinical trials, with a fourth lead asset nearing clinical entry in the next 3 months — targeting large, multi-billion-dollar inflammation and metabolic disease markets. To date, the company has raised (and spent less than 60% of) ~$550M in long-term, patient capital from mission-aligned investors such as Baillie Gifford, Kinnevik, True Ventures, FPV Ventures, Lux Capital, Dimension, Lingotto, Premji Invest, QIA, and Microsoft and Sanofi (both off the balance sheet).